Nipple Secretion Samples in Detecting Breast Cancer in Patients and Healthy Participants Undergoing Breast Cancer Screening, Breast Diagnostic Studies, or Treatment for Benign Breast Disease
NCT ID: NCT00813878
Last Updated: 2017-10-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
126 participants
OBSERVATIONAL
2001-07-31
2012-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This clinical trial is studying nipple secretion samples in detecting breast cancer in patients and healthy participants undergoing breast cancer screening, breast diagnostic studies, or treatment for benign breast disease.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To determine CEA levels in nipple secretions and blood samples from breast cancer patients and normal controls.
* To determine the sensitivity and specificity of measuring CEA levels in nipple secretions and blood samples for the detection of breast cancer.
* To validate the optical biosensor CEA levels measured in blood and nipple secretions in breast cancer patients and normal controls compared with standard protein assays.
* To develop a profile of proteins present in affected vs unaffected breasts using mass spectrometry.
OUTLINE: Patients and participants undergo nipple secretion and blood sample collection at baseline and at 1 month for evaluation of levels of carcinoembryonic antigen (CEA) and patterns of protein expression that may indicate the presence of early-stage breast cancer. Nipple secretions are obtained from both the affected and unaffected breasts via capillary, aspiration (nipple aspirate fluid \[NAF\]), and nipple blot . CEA levels are measured in serum samples, NAF, and other nipple secretions using standard CEA protein assays. Nipple secretions obtained by nipple blot are analyzed by nipple blot assay to determine the feasibility of using this technique. The results of the nipple blot assay are then compared with the results of standard protein assays to evaluate the sensitivity and specificity of the nipple blot test. CEA expression is also determined in breast tissue specimens obtained from patients undergoing diagnostic biopsy. Specimens are examined by IHC for tissue CEA levels. Proteomic profiles in NAF and serum samples are measured using liquid chromatography mass spectrometry and then compared with proteomic profiles in normal healthy controls.
Once the feasibility of the nipple blot assay has been determined, an optical biosensor will be developed to detect fluorescent-labeled antibodies directed against CEA found in serum and breast sections. Optical biosensor CEA levels measured in breast cancer patients and normal controls will then be compared to standard protein assays for evaluation of the sensitivity and specificity of biosensor measurements.
After completion of study intervention, patients and participants are followed for 5 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Normal participants
protein analysis
protein analysis
protein expression analysis
protein expression analysis
proteomic profiling
proteomic profiling
diagnostic laboratory biomarker analysis
Performed one time on study
immunohistochemistry staining method
Performed one time on study
liquid chromatography
Performed on samples collected one time on study
mass spectrometry
Performed on samples collected one time on study
fine-needle aspiration
Samples collected one time on study at the appointment for fine-needle aspiration where applicable
needle biopsy
Samples collected one time on study at the appointment for needle biopsy where applicable
radiomammography
Samples collected one time on study at the appointment for radiomammography where applicable
Breast Cancer Patients
protein analysis
protein analysis
protein expression analysis
protein expression analysis
proteomic profiling
proteomic profiling
diagnostic laboratory biomarker analysis
Performed one time on study
immunohistochemistry staining method
Performed one time on study
liquid chromatography
Performed on samples collected one time on study
mass spectrometry
Performed on samples collected one time on study
fine-needle aspiration
Samples collected one time on study at the appointment for fine-needle aspiration where applicable
needle biopsy
Samples collected one time on study at the appointment for needle biopsy where applicable
radiomammography
Samples collected one time on study at the appointment for radiomammography where applicable
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
protein analysis
protein analysis
protein expression analysis
protein expression analysis
proteomic profiling
proteomic profiling
diagnostic laboratory biomarker analysis
Performed one time on study
immunohistochemistry staining method
Performed one time on study
liquid chromatography
Performed on samples collected one time on study
mass spectrometry
Performed on samples collected one time on study
fine-needle aspiration
Samples collected one time on study at the appointment for fine-needle aspiration where applicable
needle biopsy
Samples collected one time on study at the appointment for needle biopsy where applicable
radiomammography
Samples collected one time on study at the appointment for radiomammography where applicable
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Referred to the Women's Health Center at the City of Hope National Medical Center for breast cancer screening, breast diagnostic studies, or treatment of breast disease
* Meets 1 of the following criteria:
* Asymptomatic and undergoing screening mammography (normal controls)
* Symptomatic and undergoing diagnostic mammography
* History of an abnormal mammogram and undergoing stereotactic or ultrasound-guided fine-needle aspiration or core needle biopsy
* Recently diagnosed biopsy-proven unilateral breast cancer prior to initiation of surgical or systemic therapy
* No prior breast surgery or surgical biopsy that removed the current breast pathology
* No prior breast reconstruction or breast reduction surgery that altered the ductal drainage pattern in the affected breast
PATIENT CHARACTERISTICS:
* No other cancer within the past 5 years except skin cancer
* Not pregnant or nursing
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
18 Years
120 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
City of Hope Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John Yim, MD
Role: PRINCIPAL_INVESTIGATOR
City of Hope Comprehensive Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
City of Hope Medical Center
Duarte, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHNMC-00080
Identifier Type: -
Identifier Source: secondary_id
CDR0000629067
Identifier Type: REGISTRY
Identifier Source: secondary_id
00080
Identifier Type: -
Identifier Source: org_study_id